Leerink Partnrs Issues Optimistic Estimate for AGIO Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Analysts at Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now expects that the biopharmaceutical company will post earnings per share of ($0.34) for the year, up from their previous forecast of ($0.37). The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($0.46) per share. Leerink Partnrs also issued estimates for Agios Pharmaceuticals' Q4 2024 earnings at ($1.84) EPS, Q1 2025 earnings at ($1.78) EPS, Q2 2025 earnings at ($1.81) EPS, Q3 2025 earnings at ($1.80) EPS, Q4 2025 earnings at ($1.76) EPS, FY2025 earnings at ($7.15) EPS and FY2026 earnings at ($6.57) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 2,051.38% and a negative return on equity of 2.93%.

Other research analysts have also issued reports about the company. Royal Bank of Canada increased their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 10th. Scotiabank increased their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday, December 9th. Cantor Fitzgerald restated an "overweight" rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Finally, StockNews.com raised Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, November 9th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, Agios Pharmaceuticals presently has a consensus rating of "Hold" and an average price target of $56.33.

Agios Pharmaceuticals Stock Up 1.5 %

Shares of Agios Pharmaceuticals stock traded up $0.49 during mid-day trading on Monday, reaching $33.30. 710,751 shares of the stock traded hands, compared to its average volume of 764,350. The business has a 50-day moving average of $35.76 and a 200 day moving average of $43.50. Agios Pharmaceuticals has a fifty-two week low of $24.88 and a fifty-two week high of $62.58. The stock has a market capitalization of $1.90 billion, a PE ratio of 2.93 and a beta of 0.88.

Institutional Trading of Agios Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in AGIO. Venturi Wealth Management LLC bought a new position in Agios Pharmaceuticals in the 4th quarter valued at about $33,000. Wingate Wealth Advisors Inc. acquired a new stake in Agios Pharmaceuticals during the 4th quarter worth approximately $53,000. Sterling Capital Management LLC raised its holdings in Agios Pharmaceuticals by 818.0% during the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after purchasing an additional 1,587 shares during the last quarter. KBC Group NV raised its holdings in Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 611 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 363 shares during the last quarter.

Insider Transactions at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of the company's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now owns 18,906 shares in the company, valued at $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.93% of the stock is owned by company insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.